Recent Updates
Recently added Catalysts
CDT Positive Sentiment

CDT Notes Sarborg’s Sale of Cryptocurrency Trading Agent

Key Takeaway: CDT Equity Inc. acknowledged Sarborg Limited's announcement about selling its cryptocurrency trading agent for $12.5 million. Following the sale, CDT maintains a royalty-free license to the trading agent for its treasury operations. The company continues to focus on advancing therapeutic assets through innovation and strategic partnerships.

Market Sentiment Analysis

POSITIVE FACTORS

  • CDT retains a royalty-free license to the trading agent.
  • The sale of the trading agent is valued at $12.5 million.
  • CDT is focused on enhancing therapeutic assets.

Full Press Release Details

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) notes the announcement made by Sarborg Limited (“Sarborg”) on November 19, 2026 regarding the sale of its cryptocurrency trading agent for a total consideration of $12.5 million.
Whilst CDT Equity has not implemented a corporate treasury reserve strategy in BTC in 2026, it retains a perpetual, royalty-free license to the cryptocurrency trading agent within its treasury operations following completion of the transaction.
Sarborg’s announcement can be found here: Sarborg Sells Cryptocurrency Trading Agent to Ebers Tech for $12.5 Million or at https://sarborg.com/news

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors CDT Equity Inc. Info@cdtequity.com

Frequently Asked Questions

What did CDT note about Sarborg's announcement?

CDT noted Sarborg's sale of its cryptocurrency trading agent for $12.5 million.

What license does CDT retain after the sale?

CDT retains a royalty-free license to the trading agent for its treasury operations.

What is the focus of CDT Equity Inc.?

CDT focuses on advancing high-potential therapeutic assets through innovation.

What was the total consideration for the trading agent?

The total consideration for the trading agent was $12.5 million.

Last updated: Nov 19, 2026